After more than a decade of failed drug development efforts, osteoarthritis remains one of biopharma’s most stubborn challenges. Despite affecting more than 600 million people worldwide, no therapy approved in Europe or the United States has yet been shown to slow or modify disease progression. Against that backdrop, 4Moving Biotech (4MB) is betting that a familiar drug class, GLP-1 receptor agonists, can succeed where others have fallen short.
